Impact of early nonadherence to oral antipsychotics on clinical and economic outcomes among patients with schizophrenia

Advances in Therapy

Volumn 30, Issue 3, 2013, Pages 286-297

  Offord, Steve ^a   Lin, Jay ^b   Mirski, Dario ^a   Wong, Bruce ^c  

^a OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^b Novosys Health   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Early discontinuation; Hospitalization; Medical possession ratios; Medication adherence; Psychiatry; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL PHARMACY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; ICD-9-CM; LENGTH OF STAY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; OUTCOME ASSESSMENT; SCHIZOPHRENIA; TREATMENT REFUSAL; TREATMENT WITHDRAWAL; YOUNG ADULT; ADOLESCENT; COHORT ANALYSIS; ECONOMICS; HEALTH SERVICE; HOSPITALIZATION; MENTAL HEALTH SERVICE; STATISTICS AND NUMERICAL DATA; UNITED STATES; UTILIZATION; STATISTICS; UTILIZATION REVIEW;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HEALTH SERVICES; HOSPITALIZATION; HUMANS; LENGTH OF STAY; MALE; MEDICATION ADHERENCE; MENTAL HEALTH SERVICES; MIDDLE AGED; SCHIZOPHRENIA; UNITED STATES; YOUNG ADULT;

EID: 84891600999     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0016-5     Document Type: Article

References (26)

1. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67-76.
2. Vita A, Corsini P, Bonomi S, Sacchetti E, Cesana BM. Factors affecting antipsychotic drug discontinuation in the treatment of schizophrenia: evidence from a naturalistic, retrospective, 18-month follow-up study. Schizophr Res. 2008;104:302-4.
3. Haro JM, Novick D, Suarez D, Roca M. Antipsychotic treatment discontinuation in previously untreated patients with schizophrenia: 36-month results from the SOHO study. J Psychiatr Res. 2009;43:265-73.
4. Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, doubleblind, flexible-dose, multicenter study. J Clin Psychiatry. 2008;69:106-13.
5. Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006;67:453-60.
6. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry. 2004;161:692-9.
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
8. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9- CM and ICD-10 administrative data. Med Care. 2005;43:1130-9.
9. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Interventional Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-23.
10. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med. 2005;3:1-10.
11. McCombs J, Zolfaghari S, Ganapathy V. Impact of drug treatment history on comparative effectiveness research in schizophrenia. Value Health. 2011;14:679-86.
12. Moisan J, Gregoire JP. Patterns of discontinuation of atypical antipsychotics in the province of Quebec: A retrospective prescription claims database analysis. Clin Ther. 2010;32(Suppl. 1):S21-31.
13. Yen CF, Chen CS, Ko CH, et al. Relationships between insight and medication adherence in outpatients with schizophrenia and bipolar disorder: prospective study. Psychiatry Clin Neurosci. 2005;59:403-9.
14. Altamura AC, Mauri M. Plasma concentrations, information and therapy adherence during long- term treatment with antidepressants. Br J Clin Pharmac. 1985;20:714-6.
15. Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin. 2007;23:2305-12.
16. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull. 2008;34:173-80.
17. Verdoux H, Lengronne J, Liraud F, et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand. 2000;102:203-10.
18. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241-7.
19. Subotnik KL, Nuechterlein KH, Ventura J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011;168:286-92.
20. Law MR, Soumerai SB, Ross-Degnan D, Adams AS. A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia. J Clin Psychiatry. 2008;69:47-53.
21. Weiden PJ, Kozma C, Grogg A, Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv. 2004;55:886-91.
22. Kim B, Lee S, Yang YK, Park J, Chung Y. Long- acting injectable antipsychotics for first-episode schizophrenia: the pros and cons. Schizophr Res Treatment. 2012;2012:1-8.
23. Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res. 2011;3:9-14.
24. Fuller M, Shermock K, Russo P, et al. Hospitalisation and resource utilisation in patients with schizophrenia following initiation of risperidone long-acting therapy in the Veterans Affairs Healthcare System. J Med Econ. 2009;12:317-24.
25. Niaz OS, Haddad PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand.2007;116:36-46.
26. Prikryl R, Prikrylova KH, Vrzalova M, Ceskova E. Role of long-acting injectable second-generation antipsychotics in the treatment of first-episode schizophrenia: a clinical perspective. Schizophr Res Treatment. 2012;2012:1-7.